Vantage logo

Disaster strikes for Akebia

Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?

Vantage logo

Roxadustat moves on to the regulators

A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…